Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin

OBJECTIVE: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to examine the toxicity and response rates of weekly paclitaxel and carboplatin as...

Descripción completa

Detalles Bibliográficos
Autores principales: Dessai, S. B., Chakraborty, S., Babu, T. V. S., Nayanar, S., Bhattacharjee, A., Jones, J., Balasubramanian, S., Patil, Vijay M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
METRONOMIC THERAPY IN OVARIAN CANCER: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873699/
https://www.ncbi.nlm.nih.gov/pubmed/27275450
http://dx.doi.org/10.4103/2278-330X.181629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873699/
https://www.ncbi.nlm.nih.gov/pubmed/27275450
http://dx.doi.org/10.4103/2278-330X.181629

Ejemplares similares